{
    "Trade/Device Name(s)": [
        "BD Veritor\u2122 System for Rapid Detection of Flu A + B Laboratory Kit"
    ],
    "Submitter Information": "BD Diagnostic Systems, Point of Care (Becton, Dickinson & Co.)",
    "510(k) Number": "K160164",
    "Predicate Device Reference 510(k) Number(s)": [
        "K120049",
        "K121797",
        "K132256",
        "K132693",
        "K133138",
        "K151301",
        "K152874"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "GNX"
    ],
    "Summary Letter Date": "January 22, 2016",
    "Summary Letter Received Date": "January 27, 2016",
    "Submission Date": "January 18, 2016",
    "Regulation Number(s)": [
        "21 CFR 866.3330"
    ],
    "Regulation Name(s)": [
        "Influenza virus serological reagents"
    ],
    "Analyte Class(es)": [
        "virology",
        "microbiology"
    ],
    "Analyte(s)": [
        "Influenza A viral nucleoprotein antigen",
        "Influenza B viral nucleoprotein antigen"
    ],
    "Specimen Type(s)": [
        "Nasopharyngeal wash",
        "Nasopharyngeal aspirate",
        "Nasopharyngeal swab in transport media"
    ],
    "Specimen Container(s)": [
        "Transport media"
    ],
    "Instrument(s)/Platform(s)": [
        "BD Veritor\u2122 System Reader",
        "BD Veritor\u2122 System for Rapid Detection of Flu A + B test device"
    ],
    "Method(s)/Technology(ies)": [
        "Chromatographic immunoassay",
        "Immunochromatographic assay"
    ],
    "Methodologies": [
        "Antigen detection"
    ],
    "Submission Type(s)": [
        "Kit",
        "Assay",
        "Reagent",
        "Device",
        "Reader"
    ],
    "Document Summary": "FDA 510(k) summary for BD Veritor System for Rapid Detection of Flu A + B Laboratory Kit, a chromatographic immunoassay for influenza A and B antigen detection in respiratory samples",
    "Indications for Use Summary": "Aid in direct and qualitative detection of influenza A and B viral nucleoprotein antigens from nasopharyngeal wash, aspirate, and swab samples in transport media from symptomatic patients to differentiate between influenza A and B; negative results are presumptive and should be confirmed by viral culture or FDA-cleared molecular assay",
    "fda_folder": "Microbiology"
}